Welcome to the Oncomine Blog
Evaluating NGS technologies for in-house comprehensive genomic profiling
11/13/2024 |
Research
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic...
-
Genomic Profiling from Initial Assessment to Detection of Measurable Residual Disease (MRD): How NGS Can Rapidly Deliver Key Insights for Myeloid Neoplasms
In his recent webinar, Dr. Bevan Tandon makes a compelling case for how next-generation sequencing (... -
Next-Generation Sequencing (NGS) for Clonality Testing
Lymphoproliferative disorders such as acute lymphoblastic leukemia (ALL), lymphomas, and multiple my... -
Using Next-Generation Sequencing (NGS) to Derive Key Insights in MPN Testing
Myeloproliferative neoplasms (MPNs) are a heterogeneous group of disorders that include essential th... -
What is Biomarker Testing and Why is it Important in Oncology?
Thermo Fisher Scientific is committed to bringing advanced molecular testing to clinicians and their... -
Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML)
AML Overview Acute myeloid leukemia (AML) is a highly heterogenous group of malignancies, driven by ... -
RET Aberrations and EGFR Exon 20 Insertions Testing in the Complex NSCLC Biomarker Landscape
In his recent OncomineWorld webinar, Dr. Fernando López-Ríos, MD, PhD (Department of Pathology, 12 d... -
Evaluation of Rapid Next-Generation Sequencing for the Study of Acute Myeloid Leukemia
In a recent GenomeWeb webinar, Rapid next-generation sequencing for the study of acute myeloid leuke... -
Collaborating Early to Advance Precision Medicine – A Look Inside Thermo Fisher’s CDx Program with Garret Hampton
Companion diagnostic (CDx) tests are powerful tools in precision medicine and help advance more wide... -
The Impact of Rapid Molecular Diagnosis on Precision Medicine in Acute Myeloid Leukemia
Advances in next-generation sequencing have improved our understanding of the complexity and molecul...